1. Home
  2. ADT vs GKOS Comparison

ADT vs GKOS Comparison

Compare ADT & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADT Inc.

ADT

ADT Inc.

HOLD

Current Price

$6.75

Market Cap

5.2B

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$102.16

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADT
GKOS
Founded
1874
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
6.0B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
ADT
GKOS
Price
$6.75
$102.16
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$7.75
$126.92
AVG Volume (30 Days)
14.0M
1.0M
Earning Date
04-30-2026
04-29-2026
Dividend Yield
3.07%
N/A
EPS Growth
29.63
N/A
EPS
N/A
N/A
Revenue
$5,128,607,000.00
$507,442,000.00
Revenue This Year
$1.90
$23.32
Revenue Next Year
$2.91
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
4.70
32.33
52 Week Low
$6.27
$73.16
52 Week High
$8.94
$148.11

Technical Indicators

Market Signals
Indicator
ADT
GKOS
Relative Strength Index (RSI) 40.22 28.38
Support Level $6.70 $92.38
Resistance Level $8.27 $102.80
Average True Range (ATR) 0.15 7.36
MACD -0.02 -4.94
Stochastic Oscillator 12.99 1.08

Price Performance

Historical Comparison
ADT
GKOS

About ADT ADT Inc.

ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: